Expertise in
3
conditions

Satoru Nakagawa

Niigata, JP 
Expertise in
3
conditions
Niigata, JP 

Overview

Satoru Nakagawa practices practicing medicine in Niigata, Japan.

Mr. Nakagawa is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Esophageal Cancer, Stomach Cancer, Chronic Erosive Gastritis, Gastrectomy, and Gastrostomy.

He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Niigata, Japan
Other Locations
Chuo, 9518566, Japan
Odate, Japan
Tsugaru, 0370074, Japan
Aomori, 0370074, Japan
Hirosaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3

47 Total Publications

Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502.
Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502.
Journal: Esophagus : official journal of the Japan Esophageal Society
Published: July 07, 2026

Frequently Asked Questions about Satoru Nakagawa

Is Satoru Nakagawa a top-rated expert for Esophageal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Satoru Nakagawa is classified as an Advanced expert for Esophageal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Satoru Nakagawa participate in research or clinical trials?

Yes. Satoru Nakagawa has published 47 articles and abstracts on conditions like Esophageal Cancer. You can view a list of Satoru Nakagawa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nakagawa's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile